Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...
These high attrition rates compared with those of other therapeutic areas can be explained in part by particular characteristics of oncology drugs, 4 including a narrow therapeutic index, complex ...
PRINCETON, NJ--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the ...
In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready pediatric dose selection with fewer ...
One PK/PD model helps researchers predict the disposition of a drug from the body and its penetration to the target organs. The model incorporates data from animal tests on the new drug and on a ...
Y-mAbs presented preclinical PK data for CD38-SADA at the 2025 AACR Annual Meeting, supporting its cancer treatment development. Y-mAbs Therapeutics, Inc. announced the presentation of preclinical and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results